BioPharmSignal logoBioPharmSignal

Biotech News

Supernus Announces Second Quarter 2026 Financial Results

Supernus (SUPN)SupernusEarnings

Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% compared to the same period last year.

Related news

SUPNSupernus2026-07-22 21:05 EST

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

TNXPTonix Pharmaceuticals2026-08-10 11:00 EST

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

AXSMAxsome2026-08-10 11:00 EST

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

ECORelectroCore2026-08-06 20:05 EST

electroCore Announces Second Quarter 2026 Financial Results

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Xeris Biopharma Reports Second Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Supernus

CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...

Recent company news

SUPNSupernus2026-08-03 10:35 EST

Supernus Announces Second Quarter 2026 Financial Results

SUPNSupernus2026-08-03 10:30 EST

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

SUPNSupernus2026-07-22 21:05 EST

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

SUPNSupernus2026-07-14 12:30 EST

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

SUPNSupernus2026-05-27 20:30 EST

Supernus Pharmaceuticals to Participate in June Investor Conferences

Stock data

Close
45.85 USD
Market cap
2.56B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States